T-705 (favipiravir) inhibition of arenavirus replication in cell culture - Wikidata - awgldk - TriplyDB

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

http://www.wikidata.org/entity/Q24633241

about

The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses Progress in the experimental therapy of severe arenaviral infections Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Activity of a phenolic dibenzylsulfide against New World arenavirus infections Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir.Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters.Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.Reverse Genetics Approaches to Control Arenavirus.Highlights in antiviral drug research: antivirals at the horizon.Animal models, prophylaxis, and therapeutics for arenavirus infections.Current drug discovery strategies against arenavirus infections.Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever.Extinction of West Nile virus by Favipiravir through lethal mutagenesis.Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.Novel drug discovery approaches for treating arenavirus infections.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Protracted symptoms in lymphocytic choriomeningitis: a case report.Ribavirin can be mutagenic for arenaviruses.Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State.Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.Nucleosides for the treatment of respiratory RNA virus infections.Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for use with Infected Organ Transplant Recipients.

P2860

Q21089768-7D8C237F-88AF-457B-966E-C22488A15424 Q21092271-E52013FE-9288-47CB-8D4D-B9A0C7C8779F Q24276386-53EDF23C-F14A-4FF6-AFF8-6431633D39AB Q26742028-A5AAA667-7496-4B85-BAEF-C919811A2E0A Q27024953-0DBAD168-D4E7-4187-B5CC-A7C5E7C4C72F Q28477434-ED57D0AA-1AEB-4332-ADB3-D74B66E84E63 Q28537976-96D45085-BE30-4D3A-A65C-6540DC1DDC57 Q30426020-8CE9F6E8-4213-482E-A87D-76FAD69672A4 Q33433096-44EE85A4-1609-4CE0-81FD-6017425FAC52 Q33948876-9253DB4E-E528-4D57-B733-B8B8BF8B110E Q34274569-CC14361C-C0C2-41DB-81A8-CAC15098B32E Q34374652-A0196C05-28AC-4520-9305-B43C7F9CCE65 Q34556364-C1B4F079-E79D-4EE1-A3F5-E901067641A8 Q35624775-352494F2-AA45-4FFA-A519-B773C9BFAC19 Q35952190-93025F70-89F4-4FB8-B177-EFFC76BB9ECC Q36146469-C57EFDA1-4591-40E0-BC54-F07EF3192BF5 Q37120083-5C23CEC0-CCB8-4B47-BFB8-C3EDDB0BC18D Q37263923-08075E95-1BD1-4D5F-8BE5-9492011C765D Q37543755-3E9875BF-2289-4AB8-8A90-2BE0BBA8AD47 Q38007145-16BB42C5-1024-46DD-A0BD-7B8B46F7D75D Q38061427-308D93A4-C14F-4A9E-9C3B-9F8812824A9A Q38067504-4821AD8B-3B0E-47EA-861D-70A1F3B9D636 Q38069359-1EA757E1-98C4-4EB0-BA56-4C50A6707132 Q38565357-6D82500E-B92A-40E0-B8C0-2C876C505C7B Q38605122-BCBEB46F-B563-48D5-8067-292ACD0B8A7B Q38638782-7FE16061-1CA7-4450-A7A9-293FBB51EBBC Q38735837-78D611A8-D9E6-47F9-96FD-854F990AED23 Q38833628-F55D4F30-8395-4BA6-A52C-F95F8E9465ED Q39209050-766E41F1-D0DE-468D-A58E-53153F083127 Q39544616-DBFE5DE3-0BCC-4CC2-AE42-00C5F080C83C Q40063157-EED98F03-D47A-4A3C-9F13-2F01D3A8CFEB Q40105589-AA7A925A-C51E-4D4F-9B94-F5FA396D2501 Q42110040-C5863C1B-5B11-47C8-8417-2BF6638161B1 Q45324172-F2777FF3-9EF7-4B8A-83A2-F03404FAA334 Q46768300-5BFBEB41-3D7C-4FDB-9B3B-2B81DFBCC1E8 Q52644426-B87641BE-6C82-43AE-9ABB-30130DE4FDB9 Q54211351-4881C0C7-6EFA-40B0-A364-F9AEF1407EFA

P2860

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

http://www.wikidata.org/entity/Q24633241

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@ast

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@en

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@nl

type

label

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@ast

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@en

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@nl

prefLabel

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@ast

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@en

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@nl

P1433

Q24633241-21819DF8-4608-4C1D-978C-360815DD31C6

P1476

Q24633241-9E0A5265-B636-4B9F-8BF0-F82B7A745E59

P2093

Q24633241-1193E1DB-EAF0-4509-B7C9-F3D9B7995CC0

Q24633241-33FF688D-6539-44C3-BB73-0E676AC64B9A

Q24633241-3E57F329-3962-4827-94FD-CB7E77A2AF12

Q24633241-4A06AD3B-DB0A-4348-9DCB-1619B201D445

Q24633241-5F413BCE-49D2-4260-8F58-EFB8821B98B9

Q24633241-61AA4CC7-00A3-4498-9EEF-C607356A8C2D

Q24633241-921F78C8-3A93-486D-8B82-813DF5BD715A

Q24633241-9A6A99BD-A533-43E2-B9B1-E320FADE1F83

Q24633241-D2C48552-826A-4AC9-861F-331C17ECF207

Q24633241-F693CC70-5A8E-46C4-9D07-7877720EF55D

P2860

Q24633241-06DA07BA-908D-42DC-88DC-BB6B02CF8BC8

Q24633241-20CCD514-67CF-4DE5-834E-F3E1D8B32866

Q24633241-21D17927-86EA-4BCC-962D-05437199B91B

Q24633241-2735F14E-78B3-4A9E-9DFE-9EF14F7B2A0D

Q24633241-3730EB7B-4275-4432-8EC2-53CF09155CF6

Q24633241-3C24784A-D362-4FD5-A5CF-A5D65FDA4C24

Q24633241-47BD1133-08DA-4629-A55E-F1BD760B46D7

Q24633241-551AAD11-290E-4D24-BBCB-88DCDD87DD11

Q24633241-6239F123-8FB0-4C4E-A7C9-821BCF2FEDE1

Q24633241-625ECD6F-B75B-412F-AF67-0BF18088E189

P304

Q24633241-D4C03931-09EF-46F4-8093-D6FC6AFCD39C

P31

Q24633241-932F77EE-AD84-4C20-B79E-E0261D93607D

P3181

Q24633241-8CC052C8-F9AF-4F00-9E3A-94CB9A8E2A67

P356

Q24633241-4369C358-9787-4E3F-89FE-F63D20127AAD

P407

Q24633241-FFBA8079-5F24-45F8-905D-9E3C93532258

P433

Q24633241-16EF36A3-7688-49CC-9EC0-EDA0DBBA8343

P478

Q24633241-164B62A5-592D-46C7-A120-D178CD52FD76

P50

Q24633241-9FEEE7D8-EE7F-4DC9-998D-ACEAB0095605

P577

Q24633241-F0ECC44B-C303-4E2F-8160-D46F14293407

P698

Q24633241-1BC4C429-ABA8-489D-9BA6-3B55FDCDB218

P921

Q24633241-3083E344-BA0C-4D60-B326-0D04A4AE7361

Q24633241-9EEA5F17-5FD4-4031-8F80-03E7EDEC7083

P932

Q24633241-D59DF6A1-0942-4328-9C83-A4437DA0C356

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

T-705 (favipiravir) inhibition of arenavirus replication in cell culture

@en

P2093

Alexander N Freiberg

http://www.w3.org/2001/XMLSchema#string

Andrew Russell

http://www.w3.org/2001/XMLSchema#string

Brian B Gowen

http://www.w3.org/2001/XMLSchema#string

Emily L Messina

http://www.w3.org/2001/XMLSchema#string

Jack H Nunberg

http://www.w3.org/2001/XMLSchema#string

Juan-Carlos de la Torre

http://www.w3.org/2001/XMLSchema#string

Michael R Holbrook

http://www.w3.org/2001/XMLSchema#string

Michelle Mendenhall

http://www.w3.org/2001/XMLSchema#string

Terry Juelich

http://www.w3.org/2001/XMLSchema#string

Yousuke Furuta

http://www.w3.org/2001/XMLSchema#string

P2860

NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents

Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106

Ribavirin--current status of a broad spectrum antiviral agent

Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

P304

782-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4475379

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.01219-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21115797

http://www.w3.org/2001/XMLSchema#string

P921

P932

3028760

http://www.w3.org/2001/XMLSchema#string